More on SMMT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $17.28 |
|
|||
| Open | $18.20 | ||||
| 52 Wk High | $19.75 | ||||
| 52 Wk Low | $4.26 | ||||
| Day High | $18.32 | ||||
| Day Low | $17.24 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,803,384 | ||||
- Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy
- UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
- H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
- Summit Therapeutics plc (SMMT) Reiterated at Overweight by Cantor Fitzgerald
- Form 8-K Summit Therapeutics Inc. For: Aug 25
- Guggenheim Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
- H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
- Akeso's ivonescimab beats durvalumab in biliary tract cancer trial
- Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Tria
- Summit Therapeutics publishes HARMONi Phase III lung cancer trial data
Entities mentioned with SMMT
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Equity Offerings | View Related Stories »
- S3 | View Related Stories »
- Show More...
